Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2014, Pages

  Johansen, Helle Krogh ^a   Gøtzsche, Peter C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; MAGNESIUM; NYSTATIN; POTASSIUM; ANTIFUNGAL AGENT;

ACUTE LEUKEMIA; CANCER PATIENT; DEATH; DRUG EFFECT; ESOPHAGUS CANDIDIASIS; FUNGAL COLONIZATION; GASTROINTESTINAL DISEASE; HUMAN; INFUSION RELATED REACTION; INFUSION RELATED TOXICITY; KIDNEY FAILURE; LIVER DISEASE; MALIGNANT NEOPLASM; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; COMPARATIVE STUDY; COMPLICATION; CONFIDENCE INTERVAL; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MYCOSES; NEOPLASM; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CONFIDENCE INTERVALS; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; MYCOSES; NEOPLASMS; NEUTROPENIA; NYSTATIN; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942748833     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000239.pub2     Document Type: Review

References (62)

1. Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373-8. 3006733
2. Anaissie EJ, Darouiche RO, Abi Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clinical Infectious Diseases 1996;23:964-72. 3006735
3. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-106. 3006737
4. Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. American Journal of Hematology 2002;71(4):260-7. 3006739
5. Lake D, Kunzweiler J. A randomized trial of fluconazole vs. amphotericin B for the treatment of esophageal candidiasis in the adult cancer patient. Proceedings of the Annual Meeting of American Society for Clinical Oncology. 1991:344 (abstract 1222). 3006741
6. Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996;42:308-14. 3006742
7. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. American Journal of Medicine 1998;105(6):478-83. 3006744
8. Lapierre V, Marie J-P, Pico JL, Molina A, Andremont A, Lagrange P. Intravenous fluconazole (Flu) versus intravenous amphotericin B (AmB) in the management of febrile neutropenic patients: a multicentric randomized study. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 1992, Anaheim, California. 1992:214 (abstract 624). 3006746
9. Marie JP, Lapierre V, Pico J, Vekhoff A, Molina L, Andremont A, et al. Etude multicentrique randomisée fluconazole iv versus amphotéricine B iv chez le patient neutropénique et fébrile. Cahiers d'Oncologie 1993;2:171-3. 3006747
10. Viscoli C. European studies of fluconazole (F) vs amphotericin B (AmB) in febrile neutropenic cancer patients. 7th European Congress of Clinical Microbiology and Infectious Diseases, March 26 to March 30, 1995, Vienna, Austria. 1995:14 (abstract 70). 3006748
11. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Annals of Internal Medicine 1994;120:913-8. 3006750
12. Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Investigation 1991;3:258-65. 3006752
13. Groll AH, Just-Nuebling G, Kurz M, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. Journal of Antimicrobial Chemotherapy 1997;40:855-62. 3006754
14. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. European Journal of Clinical Microbiology and Infectious Diseases 1994;13:330-7. 3006755
15. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematology and Blood Transfusion 1990;33:546-50. 3006757
16. Finke R. [Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]. Mycoses 1990;33 Suppl 1:42-54. 3006758
17. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. Journal of Antimicrobial Chemotherapy 1993;31(6):973-84. 3006759
18. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. Journal of Antimicrobial Chemotherapy 1991;27(3):369-76. 3006760
19. Schuler U, Ehninger G, Brammer K. Oral fluconazole (F) vs oral polyenes (P) as antimycotic prophylaxis in neutropenia: an European multicenter study. Annals of Hematology 1992;65:A120, abstract 356. 3006761
20. Milliken S, Gore M, Powles R, Harding M, Jameson B, Talbot D, et al. Fluconazole versus polyenes as oral anti-fungal prophylaxis in autologous and allogeneic bone marrow recipients. Bone Marrow Transplantation 1989;4 Suppl 2:27 (abstract). 3006763
21. Powles RL, Smith C, Treleaven J, Tiley C, Helenglass G. Antifungal prophylaxis with fluconazole in bone marrow transplants. Bone Marrow Transplantation 1990;5 Suppl 2:135, abstract 291. 3006764
22. Silling G, Fegeler W, Roos N, Essink M, Büchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999;42 Suppl 2:101-4. 3006766
23. Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/5-fluorocytosine. Mycoses 1999;42(3):159. 3006767
24. Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Early empiric antifungal therapy of infections in neutropenic patients with hematologic malignancies: fluconazole vs ampho B/5-FC. Annals of Hematology 1999;78 Suppl 1:S2, abstract 8. 3006768
25. Silling G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Fluconazole (FCA) versus amphotericin B/5-flucytosine (ABF) for the treatment of febrile neutropenia. Annals of Hematology 1995;70 Suppl 1:A101, abstract 28. 3006769
26. Silling-Engelhardt G, Fegeler W, Roos N, Schomaker R, Essink M, Büchner T. Early empiric antifungal treatment of infections in neutropenic patients comparing fluconazole with amphotericin B/5-flucytosine. Blood 1994;10 Suppl 1:306a. 3006770
27. Silling-Engelhardt G, Fegeler W, Roos N, Schwarz C, Essink M, Hiddeman W, et al. Interventional treatment of unexplained fever (FUO) and documented infections in neutropenic patients with hematologic malignancies: fluconazole versus ampho B/5-FC. Annals of Hematology 1992;64:A110, abstract 147. 3006771
28. Teshima H, Masaoka T, Hiraoka A, Miyazaki T, Imarmura M, Kitabayashi A. A randomised study to compare oral fluconazole with oral amphotericin B for suppression of fungal flora and prevention of fungal infection in bone marrow transplantation recipients. Drug Evaluation (Konnichi No Ishoku) 1994;7:535-42. 3006773
29. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. European Journal of Cancer 1996;32A(5):814-20. 3006775
30. Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomised multicenter trial. 20th International Congress of Chemotherapy, June 29 to July 3, 1997, Sydney, Australia. 1997:87 (abstract 3243). 3006777
31. Winston DJ, Hathorn J, Schuster M. Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomized multi-center trial. 10th International Symposium on Infections in the Immunocomprised Host, June 21-24, 1998, Davos, Switzerland. 1998:abstract no 112. 3006778
32. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. American Journal of Medicine 2000;108:282-9. 3006779
33. Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplantation 2000;25(8):853-9. 3006781
34. Ellis ME, Halim MA, Spence D, Ernst P, Clink H, Kalin M, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever - preliminary observations from a pilot, exploratory study. Journal of Infection 1995;30:141-6. 3006783
35. Reed E, Rasmussen J, Roberson P, Armitage J, Bierman P, Vose J, et al. Interim analysis of fluconazole (flu), intermittent amphotericin (ampho) and no treatment (ntx) for prophylaxis of fungal disease in bone marrow transplant (BMT) and acute leukemia (AL) patients (pts). Proceedings of the Annual Meeting of American Society for Clinical Oncology. 1993:465 (abstract A1622). 3006785
36. Timmers GJ, Zweegman S, Simoons Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplantation 2000;25(8):879-84. 3006787
37. Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine 1974;53:209-28.
38. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Ioannou S. Antifungal prophylaxis in neutropenic cancer patients - a meta-analysis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997, Toronto, Ontario, Canada. 1997:abstract no LM-88.
39. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-46.
40. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. BioMed Central Medical Research Methodology 2006;6:40.
41. Ellis ME, al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrobial Agents and Chemotherapy 1992;36:172-9.
42. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322(7286):579-82.
43. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992;326(13):845-51.
44. Groll AH, Just-Nuebling G, Kurz M, Mueller C, Nowak-Goettl U, Schwabe D, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. The Journal of Antimicrobial Chemotherapy 1997;40:855-62.
45. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238-44.
46. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000026]
47. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002033]
48. Hemminki E. Study of information submitted by drug companies to licensing authorities. BMJ 1980;280(6217):833-6.
49. Johansen HK, Gøtzsche PC. Systematic reviews of prophylactic or empirical antifungal therapy in cancer patients with neutropenia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997, Toronto, Ontario, Canada. 1997:abstract no LM-89.
50. Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients?. Support Care Cancer 1999;7(1):51-5.
51. Nakielny J. Effective and acceptable treatment for depression (letter). BMJ 1993;306:1125.
52. Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrobial Agents and Chemotherapy 1999;43(6):1417-23.
53. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. Journal of Infectious Diseases 1995;171(6):1545-52.
54. Smith GD, Egger M. Unresolved issues and future developments. BMJ 1998;316:221-5.
55. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-7.
56. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5.
57. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
58. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. European Journal of Cancer 1994;30A:430-7.
59. Working Party of the British Society for Antimicrobial Chemotherapy. Antifungal drug chemotherapy. Antifungal drug susceptibility testing. Journal of Antimicrobial Chemotherapy 1995;36:899-909.
60. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
61. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD000239]
62. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000239]